# US 2020/0016249 A1 · Il-23-p19 vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0016249 A1
- Document ID: US20200016249A1
- Status: Published application
- Kind: A1
- Application number: 16/504,971
- Filed: 2019-07-08
- Published: 2020-01-16
- Earliest claimed: 2015-06-03
- Assignees: Affiris AG
- Applicants: Affiris AG
- Inventors: Guenther STAFFLER; Dorian WINTER
- Web page: https://patentgrep.com/patent/US20200016249A1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/164: {from bacteria}
- A61K 38/20: Interleukins [IL]
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 9/00: Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K 14/54: Interleukins [IL]
- C07K 17/00: Carrier-bound or immobilised peptides (carrier-bound or immobilised enzymes C12N11/00); Preparation thereof
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group QPEGHH-WETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), and QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein said IL-23 related disease is selected from the group psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, preferably M. Alzheimer or multiple sclerosis, atopic dermatitis, graft-versus-host disease, cancer, preferably Oesophagal carcinoma, colorectal carcinoma, lung adenocarcinoma, small cell carcinoma, and squamous cell carcinoma of the oral cavity, especially psoriasis, neurodegenerative diseases or IBD.

## Claims

### Claim at position 1 (depends on 14)

1: A composition, comprising:
the peptide according to claim 14, bound to a pharmaceutically acceptable carrier.

### Claim at position 2 (depends on 1)

2: The composition according to claim 1, wherein at least one cysteine residue is bound to an N- or C-terminus of the peptide.

### Claim at position 3 (depends on 1)

3: The composition according to claim 1, wherein at least one cysteine residue is bound to an N-terminus of the peptide.

### Claim at position 4 (depends on 1)

4: The composition according to claim 1, wherein the pharmaceutically acceptable carrier is a protein carrier.

### Claim at position 5 (depends on 4)

5: The composition according to claim 4, wherein the protein carrier is selected from the group consisting of keyhole limpet haemocyanin, tetanus toxoid and diphtheria toxin.

### Claim at position 6 (depends on 1)

6: The composition according to claim 1, wherein the composition is formulated with an adjuvant.

### Claim at position 7 (depends on 17)

7: The method according to claim 17, the administering comprises intravenous, subcutaneous, intradermal or intramuscular administration.

### Claim at position 8 (depends on 1)

8: The composition according to claim 1, wherein the peptide is contained in the composition in an amount from 0.1 ng to 10 mg.

### Claim at position 9 (depends on 1)

9: The composition according to claim 1, wherein the peptide is bound to the pharmaceutically acceptable carrier by a linker.

### Claim at position 10 (depends on 9)

10: The composition according to claim 9, wherein the peptide is bound to the pharmaceutically acceptable carrier by a peptide linker and the peptide linker is selected from the group consisting of Gly-Gly-Cys, Gly-Cys, Cys-Gly and Cys-Gly-Gly.

### Claim at position 11 (depends on 1)

11: The composition according to claim 1, wherein the composition is a biepitopic vaccine.

### Claim at position 12 (depends on 1)

12: The composition according to claim 1, wherein the composition comprises two peptides, each separately bound to a pharmaceutically acceptable carrier.

### Claim at position 13 (depends on 1)

13: A vaccine kit, comprising:
the composition of claim 1 and
a further composition against a disease selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, especially type 1 diabetes; atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, atopic dermatitis, graft-versus-host disease, and cancer.

### Claim at position 14

14: A peptide, selected from the group consisting of QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9440), QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9441), QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), QPEGHHWETQQIPS (SEQ ID No. 104; p8495), QPEGHHWETQQI P (SEQ ID No. 105; p8459-1), QPEGHHWETQQI (SEQ ID No. 106; p8460), QPEGHHWETQQ (SEQ ID No. 107; p8460-1), QPEGHHWET (SEQ ID No. 108, p8461-1), QPEGHHWE (SEQ ID No. 109; p8462), TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPS (SEQ ID No. 113; p8761), TQQIPSLSP (SEQ ID No. 114; p8762), and TQQIPSLS (SEQ ID No 115; p8763).

### Claim at position 15 (depends on 14)

15: A peptide pair, comprising:
the peptide of claim 14,
wherein a first peptide of the peptide pair is selected from the group consisting of QPEGHHWETQQIPS (SEQ ID No. 104; p8495), QPEGHHWETQQI P (SEQ ID No. 105; p8459-1), QPEGHHWETQQI (SEQ ID No. 106; p8460), QPEGHHWETQQ (SEQ ID No. 107; p8460-1), QPEGHHWETQ (SEQ ID No. 98; p8461), QPEGHHWET (SEQ ID No. 108, p8461-1) and QPEGHHWE (SEQ ID No. 109; p8462) and
a second peptide of the peptide pair is selected from the group consisting of TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPSQ (SEQ ID No. 99; p8400), TQQIPSLSPS (SEQ ID No. 113; p8761), TQQIPSLSP (SEQ ID No. 114; p8762) and TQQIPSLS (SEQ ID No 115; p8763).

### Claim at position 16 (depends on 1)

16: The composition according to claim 1, wherein the peptide is selected from the group consisting of QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9440), and QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9441).

### Claim at position 17 (depends on 1)

17: A method of treating an interleukin 23 related disease, comprising:
administering the composition of claim 1 to a subject in need thereof,
wherein the interleukin 23 related disease is selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, especially type 1 diabetes; atherosclerosis, inflammatory bowel disease/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies associated vasculitides, neurodegenerative diseases, atopic dermatitis, graft-versus-host disease, and cancer.

### Claim at position 18 (depends on 11)

18: The composition according to claim 11, wherein the biepitopic vaccine comprises a peptide selected from the group consisting of QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9440), QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9441), and QPEGHHWETQQI PSLS (SEQ ID No. 103; p8322).

### Claim at position 19 (depends on 12)

19: The composition according to claim 12,
wherein a first peptide is selected from the group consisting of QPEGHHWETQQI PS (SEQ ID No. 104; p8495), QPEGHHWETQQI P (SEQ ID No. 105; p8459-1), QPEGHHWETQQI (SEQ ID No. 106; p8460), QPEGHHWETQQ (SEQ ID No. 107; p8460-1), QPEGHHWETQ (SEQ ID No. 98; p8461), QPEGHHWET (SEQ ID No. 108, p8461-1) and QPEGHHWE (SEQ ID No. 109; p8462) and
a second peptide is selected from the group consisting of TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPSQ (SEQ ID No. 99; p8400), TQQIPSLSPS (SEQ ID No. 113; p8761), TQQIPSLSP (SEQ ID No. 114; p8762) and TQQIPSLS (SEQ ID No 115; p8763).
